• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 1, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Focus on immunotherapy and patient perspective at IASLC 2019 Small Cell Lung Cancer Meeting

Bioengineer by Bioengineer
March 29, 2019
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Denver — (March 27, 2019) — While non-small cell lung cancer (NSCLC) is the more common form of lung cancer and attracts the lion’s share of the research funding, recent developments in small cell lung cancer may be shifting that slightly. In order to capitalize on these recent developments, researchers who focus on small cell lung cancer (SCLC) will gather in New York City at Memorial Sloan Kettering Cancer April 3-5, 2019 for the IASLC 2019 Small Cell Lung Cancer Meeting.

Until 2018, there had been few advances in the treatment of SCLC, which tends to be more aggressive and is often detected at later stages than NSCLC. Because of this, oncologists could offer only limited therapies to those patients.

That changed last year when the Food and Drug Administration (FDA) approved the immunotherapy nivolumab for SCLC. The research supporting that FDA recommendation, the Checkmate 032 clinical trial, was presented at the IASLC 18th World Conference on Lung Cancer (WCLC 2018) in Yokohama, Japan, in 2017. Immunotherapy for SCLC will be among the many topics discussed at the Small Cell Lung Cancer Meeting in New York.

Following WCLC 2018, researchers presented a study at the IASLC 19th World Conference on Lung Cancer in Toronto that found that adding 1L atezolizumab to standard carboplatin and etoposide prolonged overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage small cell lung cancer (ES-SCLC), as compared to carboplatin and etoposide treatment alone.

To hear more about new research on SCLC, listen to the Lung Cancer Considered podcast interview with Drs. Christine Hann and Stephen Liu.

Also new at this meeting will be a presentation from a SCLC patient, Montessa Lee. The IASLC was among the first health care associations to include a patient perspective at many of its meetings, and SCLC survivor Montessa Lee will share her inspirational message of hope, resilience and patient advocacy with a clinical audience. The Maryland special education teacher was diagnosed with a 15-centimenter tumor in 2006 but, with chemotherapy and radiation, recovered from her disease and now focuses on writing and sharing her story with other cancer groups.

The meeting also includes basic research on oncogenesis and biology of disease, preclinical therapeutic research and highlights of ongoing clinical translation.

Each of the nine sessions focuses on a unique area of research that is specific to SCLC:Pathology, Omics, Cell of Origin, Development and Tumor Initiation, Tumor Heterogeneity and Tumor Progression, Platforms for Discovery, Targeted Therapies, Biomarker, Immunotherapy for SCLC and recent and ongoing clinical trials.

“This format allows all participants to learn from and interact with investigators approaching the disease from distinct and potentially complementary angles; we believe this is ideal for young investigators and trainees getting up to speed in the area, as well as for active researchers seeking new perspectives and opportunities,” said Charles Rudin, MD, from Memorial Sloan Kettering and host of the meeting.

The meeting will begin on the evening of Wednesday April 3rd with an opening keynote lecture by Dr. Anton Berns, whose laboratory was the first to generate a genetically engineered mouse model of SCLC.

Sessions over the next day and a half will focus on advances in SCLC pathology and biomarkers; new insights from genomic, transcriptomic and metabolomic platforms; advances in understanding tumor initiation including cell of origin; analyses of tumor heterogeneity and intratumoral cell-cell interactions; progress in genetically engineered mouse modeling of disease subtypes; and therapeutic advances in targeted agents, immune modulators and others. The meeting will wrap up early afternoon on Friday April 5th.

###

For more information: Visit https://www.iaslc.org/events/iaslc-2019-small-cell-lung-cancer-meeting-sclc19 for more information including conference registration. To register as credential media, contact Chris Martin at [email protected].

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.

Media Contact
Chris Martin
[email protected]

Tags: cancerClinical TrialsResearch/DevelopmentResearchers/Scientists/Awards
Share12Tweet8Share2ShareShareShare2

Related Posts

Examining Large-Scale Gene Variants in Parkinson’s

Examining Large-Scale Gene Variants in Parkinson’s

August 1, 2025
Novel Radioimmunotherapy Successfully Targets and Eliminates Cancer Stem Cells in Ovarian Cancer Model

Novel Radioimmunotherapy Successfully Targets and Eliminates Cancer Stem Cells in Ovarian Cancer Model

August 1, 2025

Boosting Tumor Control: Radiation and ATR Inhibitor Trial

August 1, 2025

Neonatal Ultrasound: Training, Credentialing, and Quality Guidelines

August 1, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    37 shares
    Share 15 Tweet 9
  • Sustainability Accelerator Chooses 41 Promising Projects Poised for Rapid Scale-Up

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Examining Large-Scale Gene Variants in Parkinson’s

Unveiling Concealed Defects in Plastic Electronics Through Molecular Imaging

Advanced ANF/MXene-Enhanced Hydrogels Pave the Way for Flexible EMI Shielding and Wearable Sensors

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.